Drug-associated pulmonary arterial hypertension

References

• Badesch DB, Raskob GE, Elliott CG, et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest. 2010;137:376–387.
   PubMed Web of Science ®Google Scholar
• Hoeper MM, Bogaard HJ, Condliffe R, et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol. 2013;62:D42–D50.
   PubMed Web of Science ®Google Scholar
• Benza RL, Miller DP, Barst RJ, et al. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL registry. Chest. 2012;142:448–456.
   PubMed Web of Science ®Google Scholar
• Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013;62:D34–D41.
   PubMed Web of Science ®Google Scholar
• Benza RL, Gomberg-Maitland M, Demarco T, et al. Endothelin-1 pathway polymorphisms and outcomes in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2015;192:1345–1354.
   PubMed Web of Science ®Google Scholar
• Eddahibi S, Adnot S. Anorexigen-induced pulmonary hypertension and the serotonin (5-HT) hypothesis: lessons for the future in pathogenesis. Respir Res. 2002;3:9.
   PubMed Web of Science ®Google Scholar
• Gurtner HP. Aminorex and pulmonary hypertension. A review. Cor Vasa. 1985;27:160–171.
   PubMed Web of Science ®Google Scholar
• Abenhaim L, Moride Y, Brenot F, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International primary pulmonary hypertension study group. N Engl J Med. 1996;335:609–616.
   PubMed Web of Science ®Google Scholar
• Savale L, Chaumais MC, Cottin V, et al. Pulmonary hypertension associated with benfluorex exposure. Eur Respir J. 2012;40:1164–1172.
   PubMed Web of Science ®Google Scholar
• Dempsie Y, Maclean MR. Role of the serotonin transporter in pulmonary arterial hypertension. Expert Rev Clin Pharmacol. 2008;1:749–757.
   PubMedGoogle Scholar
• Paratz ED, Cunningham NJ, MacIsaac AI. The cardiac complications of methamphetamines. Heart Lung Circ. 2015;25:325–332.
   Web of Science ®Google Scholar
• Eddahibi S, Morrell N, d’Ortho MP, et al. Pathobiology of pulmonary arterial hypertension. Eur Respir J. 2002;20:1559–1572.
   PubMed Web of Science ®Google Scholar
• Eddahibi S, Adnot S. [Serotonin and pulmonary arterial hypertension]. Rev Mal Respir. 2006;23(2):4S45–4s51.
   Web of Science ®Google Scholar
• Herve P, Launay JM, Scrobohaci ML, et al. Increased plasma serotonin in primary pulmonary hypertension. Am J Med. 1995;99:249–254.
   PubMed Web of Science ®Google Scholar
• Haslam D. Weight management in obesity-past and present. Int J Clin Pract. 2016;70:206–217.
   PubMed Web of Science ®Google Scholar
• Rothman RB, Baumann MH, Dersch CM, et al. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse. 2001;39:32–41.
   PubMed Web of Science ®Google Scholar
• Bang WD, Kim JY, Yu HT, et al. Pulmonary hypertension associated with use of phentermine. Yonsei Med J. 2010;51:971–973.
   PubMed Web of Science ®Google Scholar
• Rich S, Rubin L, Walker AM, et al. Anorexigens and pulmonary hypertension in the United States: results from the surveillance of North American pulmonary hypertension. Chest. 2000;117:870–874.
   PubMed Web of Science ®Google Scholar
• Chin KM, Channick RN, Rubin LJ. Is methamphetamine use associated with idiopathic pulmonary arterial hypertension? Chest. 2006;130:1657–1663.
   PubMed Web of Science ®Google Scholar
• Hagiwara M, Tsuchida A, Hyakkoku M, et al. Delayed onset of pulmonary hypertension associated with an appetite suppressant, mazindol: a case report. Jpn Circ J. 2000;64:218–221.
   PubMedGoogle Scholar
• Nittur N, Konofal E, Dauvilliers Y, et al. Mazindol in narcolepsy and idiopathic and symptomatic hypersomnia refractory to stimulants: a long-term chart review. Sleep Med. 2013;14:30–36.
   PubMed Web of Science ®Google Scholar
• Seferian A, Chaumais MC, Savale L, et al. Drugs induced pulmonary arterial hypertension. Presse Med. 2013;42:e303–e310.
   PubMed Web of Science ®Google Scholar
• Anderson RJ, Garza HR, Garriott JC, et al. Intravenous propylhexedrine (Benzedrex(R)) abuse and sudden death. Am J Med. 1979;67:15–20.
   PubMed Web of Science ®Google Scholar
• Karaman MG, Atalay F, Tufan AE, et al. Pulmonary arterial hypertension in an adolescent treated with methylphenidate. J Child Adolesc Psychopharmacol. 2010;20:229–231.
   PubMed Web of Science ®Google Scholar
• Kloza M, Baranowska-Kuczko M, Pedzinska-Betiuk A, et al. [Serotonin hypothesis and pulmonary artery hypertension]. Postepy Hig Med Dosw. 2014;68:738–748.
   Web of Science ®Google Scholar
• Allen JA, Peterson A, Sufit R, et al. Post-epidemic eosinophilia-myalgia syndrome associated with L-tryptophan. Arthritis Rheum. 2011;63:3633–3639.
   PubMedGoogle Scholar
• Lindgren CE, Walker LA, Bolton P. L-tryptophan induced eosinophilia-myalgia syndrome. J R Soc Health. 1991;111:29–30.
   PubMedGoogle Scholar
• Campagna AC, Blanc PD, Criswell LA, et al. Pulmonary manifestations of the eosinophilia-myalgia syndrome associated with tryptophan ingestion. Chest. 1992;101:1274–1281.
   PubMed Web of Science ®Google Scholar
• Kieler H, Artama M, Engeland A, et al. Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn: population based cohort study from the five Nordic countries. BMJ. 2012;344:d8012.
   PubMed Web of Science ®Google Scholar
• Huybrechts KF, Bateman BT, Palmsten K, et al. Antidepressant use late in pregnancy and risk of persistent pulmonary hypertension of the newborn. JAMA. 2015;313:2142–2151.
   PubMed Web of Science ®Google Scholar
• Grigoriadis S, Vonderporten EH, Mamisashvili L, et al. Prenatal exposure to antidepressants and persistent pulmonary hypertension of the newborn: systematic review and meta-analysis. BMJ. 2014;348:f6932.
   PubMed Web of Science ®Google Scholar
• Guignabert C, Raffestin B, Benferhat R, et al. Serotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in rats. Circulation. 2005;111:2812–2819.
   PubMed Web of Science ®Google Scholar
• Shah SJ, Gomberg-Maitland M, Thenappan T, et al. Selective serotonin reuptake inhibitors and the incidence and outcome of pulmonary hypertension. Chest. 2009;136:694–700.
   PubMed Web of Science ®Google Scholar
• Sadoughi A, Roberts KE, Preston IR, et al. Use of selective serotonin reuptake inhibitors and outcomes in pulmonary arterial hypertension. Chest. 2013;144:531–541.
   PubMed Web of Science ®Google Scholar
• Ceylan ME, Alpsan MH. Pulmonary hypertension during lithium therapy: clinical case study. Psychopharmacol Bull. 2007;40:110–112.
   PubMedGoogle Scholar
• Caravita S, Secchi MB, Wu SC, et al. Sildenafil therapy for interferon-β-1a-induced pulmonary arterial hypertension: a case report. Cardiology. 2011;120:187–189.
   PubMed Web of Science ®Google Scholar
• Savale L, Sattler C, Gunther S, et al. Pulmonary arterial hypertension in patients treated with interferon. Eur Respir J. 2014;44:1627–1634.
   PubMed Web of Science ®Google Scholar
• Dhillon S, Kaker A, Dosanjh A, et al. Irreversible pulmonary hypertension associated with the use of interferon alpha for chronic hepatitis C. Dig Dis Sci. 2010;55:1785–1790.
   PubMed Web of Science ®Google Scholar
• Gibbons E, Promislow S, Davies RA, et al. Reversible pulmonary arterial hypertension associated with interferon-beta treatment for multiple sclerosis. Can Respir J. 2015;22:263–265.
   PubMed Web of Science ®Google Scholar
• Renard S, Borentain P, Salaun E, et al. Severe pulmonary arterial hypertension in patients treated for hepatitis C with sofosbuvir. Chest. 2016;149:e69–e73.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Kantarjian HM, Saglio G, et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2014;123:494–500.
   PubMed Web of Science ®Google Scholar
• Guignabert C, Phan C, Seferian A, et al. Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension. J Clin Invest. 2016;126:3207–3218.
   PubMed Web of Science ®Google Scholar
• Shah NP, Wallis N, Farber HW, et al. Clinical features of pulmonary arterial hypertension in patients receiving dasatinib. Am J Hematol. 2015;90:1060–1064.
   Web of Science ®Google Scholar
• Dumitrescu D, Seck C, ten Freyhaus H, et al. Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia. Eur Respir J. 2011;38:218–220.
   PubMed Web of Science ®Google Scholar
• Mattei D, Feola M, Orzan F, et al. Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient. Bone Marrow Transplant. 2009;43:967–968.
   PubMed Web of Science ®Google Scholar
• Hoeper MM, Barst RJ, Bourge RC, et al. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation. 2013;127:1128–1138.
   PubMed Web of Science ®Google Scholar
• Schermuly RT, Dony E, Ghofrani HA, et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest. 2005;115:2811–2821.
   PubMed Web of Science ®Google Scholar
• Zakrzewski D, Seferynska I, Warzocha K, et al. Elevation of pulmonary artery pressure as a complication of nilotinib therapy for chronic myeloid leukemia. Int J Hematol. 2012;96:132–135.
   PubMed Web of Science ®Google Scholar
• Breccia M, Alimena G. Second-generation tyrosine kinase inhibitors (Tki) as salvage therapy for resistant or intolerant patients to prior TKIs. Mediterr J Hematol Infect Dis. 2014;6:2014003.
   PubMedGoogle Scholar
• Quilot FM, Georges M, Favrolt N, et al. Pulmonary hypertension associated with ponatinib therapy. Eur Respir J. 2016;47:676–679.
   PubMed Web of Science ®Google Scholar
• Chari A, Hajje D. Case series discussion of cardiac and vascular events following carfilzomib treatment: possible mechanism, screening, and monitoring. BMC Cancer. 2014;14:915.
   PubMed Web of Science ®Google Scholar
• Krishnan U, Mark TM, Niesvizky R, et al. Pulmonary hypertension complicating multiple myeloma. Pulm Circ. 2015;5:590–597.
   PubMed Web of Science ®Google Scholar
• Wang X, Ibrahim YF, Das D, et al. Carfilzomib reverses pulmonary arterial hypertension. Cardiovasc Res. 2016;110:188–199.
   PubMed Web of Science ®Google Scholar
• Tabarroki A, Lindner DJ, Visconte V, et al. Ruxolitinib leads to improvement of pulmonary hypertension in patients with myelofibrosis. Leukemia. 2014;28:1486–1493.
   PubMed Web of Science ®Google Scholar
• Low AT, Howard L, Harrison C, et al. Pulmonary arterial hypertension exacerbated by ruxolitinib. Haematologica. 2015;100:e244–e245.
   PubMed Web of Science ®Google Scholar
• Kwon Y, Gomberg-Maitland M, Pritzker M, et al. Telangiectasia and pulmonary arterial hypertension following treatment with trastuzumab emtansine: a case report. Chest. 2016;149:e103–e105.
   PubMed Web of Science ®Google Scholar
• Sibaud V, Niec RE, Schindler K, et al. Ado-trastuzumab emtansine-associated telangiectasias in metastatic breast cancer: a case series. Breast Cancer Res Treat. 2014;146:451–456.
   Web of Science ®Google Scholar
• Lazarevic V, Liljeholm M, Forsberg K, et al. Fludarabine, cyclophosphamide and rituximab (FCR) induced pulmonary hypertension in Waldenstrom macroglobulinemia. Leuk Lymphoma. 2008;49:1209–1211.
   PubMed Web of Science ®Google Scholar
• Montrone D, Correale M, Franzese MG, et al. Pulmonary arterial hypertension in a chronic lymphocytic leukemia patient in treatment with rituximab. J Cardiovasc Med. 2015;16:S65.
   Google Scholar
• Liotta M, Rose PG, Escobar PF. Pulmonary hypertension in two patients treated with bevacizumab for recurrent ovarian cancer. Gynecol Oncol. 2009;115:308–309.
   PubMed Web of Science ®Google Scholar
• Mathew R, Huang J, Katta US, et al. Immunosuppressant-induced endothelial damage and pulmonary arterial hypertension. J Pediatr Hematol Oncol. 2011;33:55–58.
   PubMed Web of Science ®Google Scholar
• Alvarez PA, Saad AK, Flagel S, et al. Leflunomide-induced pulmonary hypertension in a young woman with rheumatoid arthritis: a case report. Cardiovasc Toxicol. 2012;12:180–183.
   PubMed Web of Science ®Google Scholar
• Martinez-Taboada VM, Rodriguez-Valverde V, Gonzalez-Vilchez F, et al. Pulmonary hypertension in a patient with rheumatoid arthritis treated with leflunomide. Rheumatology. 2004;43:1451–1453.
   PubMed Web of Science ®Google Scholar
• Ho RC, Ho EC, Tan CH, et al. Pulmonary hypertension in first episode infective endocarditis among intravenous buprenorphine users: case report. Am J Drug Alcohol Abuse. 2009;35:199–202.
   PubMed Web of Science ®Google Scholar
• Garrett PM. Tramadol overdose and serotonin syndrome manifesting as acute right heart dysfunction. Anaesth Intensive Care. 2004;32:575–577.
   PubMed Web of Science ®Google Scholar
• Perdreau E, Iriart X, Mouton JB, et al. Cardiogenic shock due to acute tramadol intoxication. Cardiovasc Toxicol. 2015;15:100–103.
   PubMed Web of Science ®Google Scholar
• Terra Filho M, Yen CC, Santos Ude P, et al. Pulmonary alterations in cocaine users. Sao Paulo Med J. 2004;122:26–31.
   PubMedGoogle Scholar
• Yakel DL, Jr, Eisenberg MJ. Pulmonary artery hypertension in chronic intravenous cocaine users. Am Heart J. 1995;130:398–399.
   PubMed Web of Science ®Google Scholar
• Murray RJ, Smialek Je Fau - Golle M, Golle M, et al. Pulmonary artery medial hypertrophy in cocaine users without foreign particle microembolization. Chest. 1989;96:1050–1053.
   Web of Science ®Google Scholar
• Darke S, Duflou J, Torok M. The health consequences of injecting tablet preparations: foreign body pulmonary embolization and pulmonary hypertension among deceased injecting drug users. Addiction. 2015;110:1144–1151.
   PubMed Web of Science ®Google Scholar
• Karch SB, Mari F, Bartolini V, et al. Aminorex poisoning in cocaine abusers. Int J Cardiol. 2012;158:344–346.
   PubMed Web of Science ®Google Scholar
• Ranchoux B, Gunther S, Quarck R, et al. Chemotherapy-induced pulmonary hypertension: role of alkylating agents. Am J Pathol. 2015;185:356–371.
   PubMed Web of Science ®Google Scholar
• Botros L, Van Nieuw Amerongen GP, Vonk Noordegraaf A, et al. Recovery from mitomycin-induced pulmonary arterial hypertension. Annals Ats. 2014;11:468–470.
   Google Scholar
• Joselson R, Warnock M. Pulmonary veno-occlusive disease after chemotherapy. Hum Pathol. 1983;14:88–91.
   PubMed Web of Science ®Google Scholar
• Antonioli E, Nozzoli C, Gianfaldoni G, et al. Pulmonary hypertension related to thalidomide therapy in refractory multiple myeloma. Ann Oncol. 2005;16:1849–1850.
   PubMed Web of Science ®Google Scholar
• Hattori Y, Shimoda M, Okamoto S, et al. Pulmonary hypertension and thalidomide therapy in multiple myeloma. Br J Haematol. 2005;128:885–887.
   PubMed Web of Science ®Google Scholar
• Younis TH, Alam A, Paplham P, et al. Reversible pulmonary hypertension and thalidomide therapy for multiple myeloma. Br J Haematol. 2003;121:191–192.
   PubMed Web of Science ®Google Scholar
• Lafaras C, Mandala E, Verrou E, et al. Non-thromboembolic pulmonary hypertension in multiple myeloma, after thalidomide treatment: a pilot study. Ann Oncol. 2008;19:1765–1769.
   PubMed Web of Science ®Google Scholar
• Cherifi S, Hermans P, De Wit S, et al. Acute pulmonary hypertension following paclitaxel in a patient with AIDS-related primary effusion lymphoma. Clin Microbiol Infect. 2001;7:277–278.
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Fang L, Huang JE, et al. BRIDGE: an open-label phase II trial evaluating the safety of bevacizumab + carboplatin/paclitaxel as first-line treatment for patients with advanced, previously untreated, squamous non-small cell lung cancer. J Thorac Oncol. 2011;6:109–114.
   PubMed Web of Science ®Google Scholar
• Abe K, Sakakibara T, Miyamoto Y, et al. Effect of prostaglandin E1 on pulmonary hypertension after protamine injection during cardiac surgery. Eur J Clin Pharmacol. 1998;54:21–25.
   PubMed Web of Science ®Google Scholar
• Jerath A, Srinivas C, Vegas A, et al. The successful management of severe protamine-induced pulmonary hypertension using inhaled prostacyclin. Anesth Analg. 2010;110:365–369.
   PubMed Web of Science ®Google Scholar
• Lowenstein E, Johnston WE, Lappas DG, et al. Catastrophic pulmonary vasoconstriction associated with protamine reversal of heparin. Anesthesiology. 1983;59:470–473.
   PubMed Web of Science ®Google Scholar
• Freitas CF, Faro R, Dragosavac D, et al. Role of endothelin-1 and thromboxane A2 in the pulmonary hypertension induced by heparin-protamine interaction in anesthetized dogs. J Cardiovasc Pharmacol. 2004;43:106–112.
   PubMed Web of Science ®Google Scholar
• Wong SM, Tse HF, Siu CW. Pulmonary hypertension and isolated right heart failure complicating amiodarone-induced hyperthyroidism. Heart Lung Circ. 2012;21:163–165.
   PubMed Web of Science ®Google Scholar
• Vallabhajosula S, Radhi S, Cevik C, et al. Hyperthyroidism and pulmonary hypertension: an important association. Am J Med Sci. 2011;342:507–512.
   PubMed Web of Science ®Google Scholar